Johansson, Harriet http://orcid.org/0000-0002-4131-2030
Guerrieri-Gonzaga, Aliana http://orcid.org/0000-0003-1915-1688
Gandini, Sara
Bertelsen, Bjørn-Erik http://orcid.org/0000-0001-8455-2176
Macis, Debora http://orcid.org/0000-0002-0633-2933
Serrano, Davide http://orcid.org/0000-0002-2945-4108
Mellgren, Gunnar
Lazzeroni, Matteo
Thomas, Parijatham S. http://orcid.org/0000-0003-2973-6639
Crew, Katherine D.
Kumar, Nagi B.
Briata, Irene Maria http://orcid.org/0000-0003-0767-0026
Galimberti, Viviana
Viale, Giuseppe
Vornik, Lana A.
Aristarco, Valentina
Buttiron Webber, Tania
Spinaci, Stefano
Brown, Powel H. http://orcid.org/0000-0002-3398-163X
Heckman-Stoddard, Brandy M.
Szabo, Eva http://orcid.org/0000-0003-3891-0942
Bonanni, Bernardo http://orcid.org/0000-0003-3589-2128
DeCensi, Andrea http://orcid.org/0000-0003-2635-4491
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (HHSN261201200034I, HHSN261201200034I, HHSN261201200034I)
This work was also partially supported by a grant from The University of Texas MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment.
This work was also partially supported by the Italian Ministry of Health with Ricerca Corrente and 5X1000 funds.
Article History
Received: 12 April 2023
Accepted: 4 January 2024
First Online: 18 January 2024
Competing interests
: Prof. Viale reported personal fees from Roche, AstraZeneca, Daiichi Sankyo, MSD Oncology, Agilent, and Pfizer outside the submitted work. Dr. Brown is the principal investigator of the National Cancer Institute grant that supported this clinical trial and received partial salary support from this grant during the conduct of the study; he also holds stock from GeneTex, an antibody reagent company. No other disclosures were reported.